BD (Becton, Dickinson and Company)

Advancing the world of health™ Infusate-Based Vascular Access Selection Speaker: Barb Nickel, APRN-CNS, CCRN, CRNI® July 23, 2026 2 p.m. ET / 11 a.m. PT Selecting the appropriate vascular access device (VAD) is critical, especially in clinical scenarios involving difficult intravenous (IV) access and administration of high-risk medications.

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026 to discuss the Company's financial results for its third quarter of fiscal year 2026, which ended on June 30, 2026, and to provide an update on its operations and strategy.

FRANKLIN LAKES, N.J.  (July 9, 2026) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has been named among the top-performing U.S.-based companies by TIME. The recognition reflects a data-driven evaluation of thousands of companies across employee satisfaction, financial performance and corporate sustainability.

First-ever disease focused fellowship program supports specialized endovascular training for physicians across Europe By Jane Hart, VP of Clinical Affairs, BD Interventional – Peripheral Intervention I’m proud to share the early success of BD’s partnership with the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

FRANKLIN LAKES, N.J. (July 1, 2026) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Matthew Sassone has been appointed worldwide president of BD Pharmacy Automation, a global business within the company’s Medication Management Solutions business unit, effective immediately.

BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the...

BD Issues Nationwide Recall for Specific Lots of ChloraPrep™ Clear Single Sterile 1 mL and FREPP™ Clear 1.5 mL Applicators Due to Microbial Contamination FRANKLIN LAKES, N.J. (June 06, 2026) – BD (Becton, Dickinson and Company) is voluntarily recalling lot 4032183 of ChloraPrep™ Clear 1 mL Single Sterile and lot 4073005 of FREPP™ Clear 1.5 mL applicators with paper lidding to the consumer level.

New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures. , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the introduction of the Elyra™ Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD's kidney stone care portfolio for urology teams.

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1. Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth through disciplined execution.

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025. With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis.